The efficacy and tolerability of vigabatrin as add-on therapy was assessed in patients with uncontrolled partial seizures. Ninety-seven patients entered this seven-centre, double-blind, placebo-crossover study. Vigabatrin (2 g or 3 g) or placebo was administered daily.
INTRODUCTION
Vigabatrin, a structural analogue of gammaaminobutyric acid (GABA), is an irreversible inhibitor of GABA-transaminase, the enzyme that catabolizes GABA to succinic semialdehyde'.
The resultant increase in brain GABA levels within the central nervous system has been established in animal models and in manz4. GABA is the major inhibitory neurotransmitter in the mammalian brain. A reduction in GABA concentrations has been associated with the disruption of normal neurological control and the abnormal, hypersynchronous activation of large groupings of contiguous neurones, predisposing to seizure activity'.
To date, the drug therapy of patients with epilepsy has been associated with a decrease in seizure frequency in approximately 80% of those treated5. The remaining 20% are refractory to treatment with routine antiepileptic drugs (AEDs) and require intensive therapy, often with more than one agent, to achieve optimal seizure control. The results of double-blind, placebocontrolled studies indicate that the addition of vigabatrin to standard antiepilepsy therapy can significantly decrease seizure frequency and severity in drug-refractory patients experiencing complex partial seizureP.
In these studies of vigabatrin, approximately one half of the patients receiving vigabatrin therapy experienced a 50% or greater reduction in seizure frequency compared with those receiving placebo treatment. Vigabatrin has been found to be well-tolerated, with adverse events occurring most commonly during the early phase of therapy and decreasing in incidence with continued therapy".
The results of a dose-ranging study', together with supportive evidence derived from a metaanalysis of published European placebo-controlled studies of vigabat&, indicate that doses of 1.5 g/day or greater are effective as add-on therapy for uncontrolled complex partial seizures. The majority of European studies have evaluated a 3 g daily dose of vigabatrin. Patients treated with 1.5 g/day have shown a signficant reduction of seizure frequency compared with pretreatment rates; however, this response was smaller than that observed among patients treated with higher doses"'.
The study reported here examined the efficacy and tolerability of two daily doses of vigabatrin (2g and 3 g) to define more fully the optimal effective dose in patients with complex partial seizures refractory to therapy with established AEDs. Vigabatrin therapy was added to currently prescribed AED therapy and compared with placebo in patients with resistant complex partial seizures.
METHODS
Patients of either sex, aged between 16 and 65 years, were included in the study. Eligibility required that all patients had at least nine documented complex partial seizures during the previous two months, despite a stable regimen of treatment (AEDs confirmed by steady-state plasma drug levels) with currently available AEDs, recorded in a patient diary. Seizure activity must have severely affected the patient's way of life; the patients must have been treated with stable regimens of up to three other AEDs during the two months before the study.
Patients were excluded from the study if they had a treatable seizure aetiology (e.g. metabolic or neoplastic cause), if they had experienced more than one episode of status epilepticus during the previous six months, had a history of alcoholism or drug addiction, were unable to comply with completing the seizure frequency calendars, or if they had evidence of other systemic disease that would subject them to undue risk or would compromise the objective of the study. Women of childbearing potential were excluded from the study unless an acceptable method of contraception was used. All patients gave written, informed consent, and institutional Ethical Review Committee approval was obtained at each study site.
All patients were maintained on their established AED treatments throughout the study. Other medications affecting the central nervous system were continued for as long as possible, and all concomitant medications were recorded at each clinic visit. No other investigational drugs were taken during the study.
Vigabatrin was supplied as 0.5 g tablets. Each dose of active vigabatrin or matching inactive placebo was packed in a foil sachet containing three tablets which comprised drug and/or placebo (i.e. each sachet contained 0, 2 or 3 placebo tablets and 0, 2 or 3 vigabatrin tablets. All medications were administered under doubleblind conditions according to a computergenerated randomization schedule. This crossover study was conducted in five phases (Fig. 1) . During Phase I, an initial screening was completed for each patient. This required baseline examinations including medical history and examination, seizure history, complete physical and neurological examination, full laboratory test screen, determination of plasma levels of current AEDs medication, and baseline neuropsychological testing (not presented in this report). Patients who met the entry criteria at the end of this eight-week observation period continued into Phase II. During Phase II, patients were randomized to reveive vigabatrin 2 g/day, vigabatrin 3 g/day, or placebo. Patients were evaluated after four and eight weeks of treatment, at which time the patient's seizure diary was reviewed and concomitant medication and adverse events were recorded. Patients were asked to rate any changes in the duration and severity of their seizure activity compared with the prior washout period.
Physical and neurological status was assessed at the week 4 and week 8 visits. At the end of week 8, the investigator completed a global evaluation, performed a complete laboratory test screen, and determined plasma levels of concomitant AEDs. Upon completion of this phase, patients entered Phase III, during which those patients randomized to receive vigabatrin had their dose reduced, under double-blind conditions, by 1 g/week, over a four-week period. Placebotreated patients continued to receive placebo during this phase. Comprehensive physical, neurological, and laboratory testing was conducted at the end of the four-week period (Phase III). All patients were then crossed over so that patients who had previously received vigabatrin now received the placebo for eight weeks (Phase IV), and vice versa according to the randomization schedule. In Phase IV, the frequency of patient visits and assessments of patient status followed the Phase II schedule.
Upon completion of this phase, patients entered a final four-week dose reduction period (Phase V), which was similar in design to Phase III. Following completion -of Phase V, the patient's response to vigabatrin was assessed and appropriate patients were enrolled in a long-term extension of vigabatrin treatment. Patients were offered continued vigabatrin treatment under a different trial protocol, under open conditions, if they had experienced more than a 50% reduction in seizure rate compared with placebo during vigabatrin therapy. Patients with a reduction in seizure rate of less than 50%, but whose improvement in quality of life was judged by the investigator to warrant continued vigabatrin therapy, were also offered continued treatment.
Adverse events were recorded at each clinic visit, and the relationship to therapy was assessed and coded using World Health Organizationpreferred terms. Events occurring during the dose-reduction phases were assumed to be related to the previous treatment.
The primary efficacy parameter was total seizure rate (defined as the monthly seizure rate for all seizure types, calculated for each of the four-week study periods). Baseline seizure rates were analyzed by the Kruskal-Wallis test. The data for seizure ratq were assumed to follow log-normal distribution; however, because a number of patients became seizure-free (a rate of 0), a log-transformation of rate was not possible, and so a square root transformation was conducted. Statistical analyses were performed using analysis of variance accounting for variation due to patient, dose group, treatment and treatment period. Means for the square root transformed data and for the back-transformed (squared) data are presented in this report. The carry-over effect of vigabatrin into the washout phase was assessed using square root transformed seizure rates for the run-in and washout periods. The number of seizure-free days and longest seizurefree interval between treatments were analysed by the sign-rank test.
Global evaluations of well-being were made by both the investigator and the patient and graded as 'very good effect', 'good effect', 'moderate effect', 'mild effect', 'no effect' and 'worse' and were analysed by the Cochran-Mantel-Haenszel test.
The incidence of adverse events was compared using the Chi-square statistic. Changes in laboratory data from pre-treatment baseline were assessed using the sign-rank matched pair test.
RESULTS

Patient demographics
A total of 97 patients (45 men and 52 women) ranging in age from 17 to 64 years entered the study. All patients were Caucasian. Of these, 17 patients were excluded from the analysis of efficacy; two patients withdrew because of adverse events, six patients withdrew because of non-compliance with study medication, four withdrew at their own request, and five withdrew for other reasons unrelated to therapy such as incomplete visits, inability to keep a seizure record, adverse event on placebo and insufficient seizure history for inclusion. Therefore, 80 patients were included in the analysis of drug efficacy. Eight of these patients were strictly defined as protocol violators but the reasons for the data exclusion were not likely to have affected the clinical evaluation of the drug. A subanalysis of the 72 patients who precisely met all protocal requirements was conducted. No differences were observed for the results of the 72 patients compared with those of the 80 patients included in the overall efficacy analysis, and the data from the 80-patient cohort are presented here.
Seizure-free periods
The 80 patients (41 men and 39 women) included in the analysis of efficacy ranged in age from 17 to 64 years (mean: 33.2 years). Twenty patients received vigabatrin 2 g/placebo, 22 received placebo/vigabatrin 2 g, 20 received vigabatrin 3 g/placebo, and 18 received placebo/vigabatrin 3 g. No significant differences were observed between treatment groups for any baseline demographic or clinical characteristics.
Total seizure rate
The mean monthly seizure rate decreased during vigabatrin therapy (Table 1) . A 34% reduction in the total mean back-transformed seizure rate was observed during vigabatrin therapy (21.06) compared with placebo treatment (13.83). Similarly, a 39% reduction was observed based on a total median monthly seizure frequency. Forty-two per cent (34/80) of patients had a 50% or greater reduction of seizure frequency during active treatment, compared with palcebo.
During the study, 18 patients reported seizurefree periods of at least four weeks' duration; three of these patients were excluded from the analysis of efficacy because of protocol violations. Of the remaining 15 patients, two patients receiving vigabatrin 3 g/day became seizure-free for the entire active treatment period, one continuing into the washout period. Of the other three patients receiving vigabatrin 3 g/day, three had seizure-free periods, two during the first treatment period and one during the second period extending into the washout phase. None of the eight patients receiving vigabatrin 2 g/day was seizure-free during the entire active period, but four were seizure-free during their second period and four during the first part of the active period. To summarize, two patients were seizure-free for the entire active treatment periods, 11 had seizure-free periods during the study, and two showed a placebo-response during the second four-week treatment period.
The reduction in seizure frequency during vigabatrin treatment did not appear to be dose related. As shown in Table 2 , relative to placebo, a 36% reduction in the mean back-transformed seizure rate was observed for patients receiving vigabatrin 2 g/day compared with a 31% mean reduction for patients treated with vigabatrin 3 g/day.
The number of seizure-free days and longest seizure-free period were significantly (P < 0.01) longer during vigabatrin therapy compared with placebo. The median number of seizure-free days increased from a mean of 19 days during placebo treatment, to 22 during vigabatrin therapy; the longest seizure-free period rose from six days during placebo therapy to 10.5 days during vigabatrin therapy (Fig. 2) .
Seizure severity and duration
Analysis of the reduction in seizure rate during vigabatrin therapy found a decrease in the mean seizure rate at all centres, ranging from a 22-62% overall reduction in seizures. This variation was probably due to the small number of patients recruited at some centres, and highlights the heterogeneity of this patient population.
Forty-two per cent of patients reported a reduction of seizure severity during vigabatrin therapy compared with 20% of those receiving placebo. During vigabatrin therapy, 36% of patients reported a decrease in the duration of length of individual seizures compared with 20% during the placebo treatment phases. Thirty-two per cent of patients treated with vigabatrin reported a trend towards less severe, shorter seizures during the period of active treatment; by comparison, 16% of patients reported this combination of seizure improvement during the placebo treatment phase (P = 0.06). In the second month of active treatment, more than one-third of patients (38%, n = 31) had a combination of both milder and shorter duration seizures compared with 7.5% (n = 14) on placebo (P < 0.01).
Global evaluation of well-being
A global evaluation of well-being was made by both the investigator and the patient after two months' treatment. The well-being of 23% of patients (n = 18) taking vigabatrin was assessed by the investigator as 'very good' or 'good' compared with 9% (n = 7) on placebo (P < 0.001). This concurred with patients' assessment of their own well-being. That is, 30% patients (n = 24) rated their well-being as 'very good' or 251 Seizure-free days Seizure-free periods 'good' compared with 13% (n = 10) on placebo (P c 0.01).
Tolerability
Two patients discontinued therapy because of adverse events; following three weeks of vigabatrin 2 g/day, one patient experienced depression that may have been drug-related. Another patient who had received placebo reported severe fatigue, visual impairment, nausea and vomiting throughout the first study period and subsequent washout phase.
Adverse events were reported throughout the study. One or more adverse events were reported by five patients during the baseline phase, by 36 receiving vigabatrin 2 g/day, by 27 receiving vigabatrin 3 g/day, by 26 receiving placebo (2 g/day), and 21 receiving placebo (3 g/day). The most commonly reported adverse events are reported in Table 3 . Adverse events were primarily of central nervous system origin. Dose-related increases in the incidence of adverse events occurred only for drowsiness and visual adverse events (diplopia, ataxia, visual abnormality): however, the small numbers of patients experiencing these events precludes a firm conclusion regarding the trends observed in this study. Depression was the only behavioural change reported consistently during vigabatrin treatment; aggressive reactions were reported by three patients (7.3%) receiving placebo (3 g/day) but were not reported in the vigabatrin treatment groups. Furthermore, no patient reported psychosis during this study.
No clinically significant changes were noted for any haematology or biochemistry test result and no significant drug interactions, as determined by the investigators, were observed during the study. 
DISCUSSION
The results of this study indicate that vigabatrin, when added to conventional therapy as a daily dose of either 2 or 3 g, is significantly more effective than placebo in reducing the frequency of seizures in patients suffering from uncontrolled partial seizures. Compared with placebo, vigabatrin reduced the seizure rate by 34%; 42% (34/80) of the patients had a 50% or greater reduction of seizure frequency during active treatment as compared with placebo. These response rates compare favourably with those reported in recent studies of vigabatrin'@12.
In a single-blind, placebo-controlled studyi of 101 patients with epilepsy (most with partial seizures), patients had vigabatrin 2 g/day added to current therapy for eight weeks; they could then be titrated to a maximum dose of 4 g/day over 16 weeks. The median number of seizures per month decreased from 16 during the placebo phase to five during the last eight weeks of vigabatrin therapy (a reduction of 69%; P < 0.0001). A reduction in seizure frequency of greater than 50% compared with placebo was observed in 60 (59%) of patients.
An assessment of 54 patients with drugresistant partial epilepsy who had vigabatrin added to their regimen found a decrease in median monthly seizure frequency from 12.5 episodes at baseline to 3.3 episodes after three months of therapy, and the rate was 3.9 episodes after five years of treatment".
Fifty-four per cent of patients treated under the long-term phase of that study had a 50% or greater decrease in seizure frequency at five years compared with baseline' ' .
A recent long-term study found that vigabatrin effectively reduced the seizure rate in patients with partial seizures following 52-78 months of treatment".
In this study, median monthly seizure frequency during the last two months of vigabatrin therapy was 3.5 episodes compared with 10 episodes during the initial placebo phase (P c 0.01).
Earlier studies found that while a daily dose of 1.5 g effectively reduced seizure activity compared with placeboh.', this dose was less effective than 3 g/day. In this study, the reductions in seizure rate of 36% and 31% for the 2 g and 3 g doses, respectively, suggest that no clinically relevant differences in response rate was observed between these doses compared with placebo. Two patients receiving the 3 g/day dose became seizure-free for the entire active treatment period, a seizure-free period was reported for 19% (8/42) patients receiving 2 g/day and for 13% (5/38) receiving 3 g/day. Although these trends are important, it should be recognized that the interpatient variability in studies of AEDs can confound the interpretation of some results. In this case, two patients reported seizure-free periods related to placebo treatment, one during the washout phase after placebo treatment and the other for the entire placebo period. In some cases, patients were seizure-free during the washout period following active treatment. These data highlight the need to consider the individuality of patient responses and the complexity of analysing responses to therapy.
Twice as many patients (n = 26) reported a combination of less severe and shorter duration seizures during vigabatrin treatment (32%) compared with those receiving placebo treatment (n = 13, 16%). Patient anxiety about epilepsy has been related to the length of the seizure-free period; a longer period is associated with an improvement in patient well-being". In our study, the length of the seizure free-period increased from 19 days during placebo treatment to 22 days during vigabatrin therapy. Although not statistically significant, these data indicate that the drug could contribute to a reduction in anxiety about seizure recurrence.
The incidence of adverse events during vigabatrin therapy was low and overall did not rise with increasing vigabatrin dose. Only drowsiness and visual abnormalities increased with vigabatrin dose. The only event assessed as a behavioural change consequent to vigabatrin therapy was depression, which occurred in approximately 7% of vigabatrin-treated patients and about 1% of placebo-treated patients. However, symptoms of depression are known to occur more often in patients who suffer from epilepsy than in the normal population. Aggressive reactions were not reported during vigabatrin therapy but were noted in patients receiving placebo, thereby demonstrating the extent of confounding factors associated with psychological assessments in this type of study. None of the patients in this short-term study reported psychosis.
Good seizure control and a low incidence of disturbing side-effects, together with a reduction in falls and trauma secondary to tonic and atonic seizures, contribute to an increase in the quality of life of epileptic patients'. The improvement in seizure control, together with a low incidence of adverse events, observed in this study suggest that vigabatrin therapy may play a role in improving the quality of life of patients with partial seizures.
In conclusion, the results of this study provide additional evidence for the efficacy of vigabatrin in treating patients with localized and related epilepsy, and also indicates that 2 g/day of vigabatrin is as effective as 3 g/day as add-on therapy for patients suffering from previously uncontrolled partial seizures. The tolerability profiles of these two doses were similar.
